1Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2): 69-90.
2Assef M, Rossini L, Rossini L, et al. Relevance of endoscopic ultra-sound in the management of esophagus cancer therapy[J]. Endosc Ultrasound, 2014, 3(Suppl S1) : 15-16.
3Trotti A, Colevas A, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment[J].Semln Radiat Oncol, 2003, 13(3): 176-181.
4Kloog I, Haim A, Stevens RG, et al. Global co-distribution of light at night (LAN) and cancers of prostate, colon, and lung in men[J]. Chronobiol Int, 2009, 26(1): 108-125.
5Miaskowski C, Lee K, Dunn L, et al. Sleep-wake circadian activity rhythm parameters and fatigue in ontology patients before the initia- tion of radiation therapy[J]. Cancer Nurs, 2011, 34(4): 255-268.
6Kotronoulas, G, Wengstrom Y, Kearney N. A critical review of women's sleep-wake patterns in the context of neo-/adjuvant chemo- therapy for early-stage breast cancer[J]. Breast, 2012, 21(2): 128 -141.
7Blask DE, Sauer LA, Dauchy RT. Melatonin as a chronobiotic/anti- cancer agent: celluar, biochemical,and molecular mechanisms of ac- tion and their implication for clrcadian-based cancer therapy[J]. Curr Top Med Chem, 2002, 2(2): 113-132.
8Yi C,Mu L, de la Longrais IA,et al.Tha circadian gene NPAS2 is a novel prognostic biomarker for breast cancer[J]. Breast Cancer Res Treat, 2010, 120(3): 663-669.
9Zhu Y,Leaderer D, Guss C, et al. Ala394Thr polymorphism in the clock gene NPAS2: a circadian modifier for the risk of non-Hodgkin's lymphoma[J]. Int J Cancer, 2007, 120 (2) : 432- 435.
10Zhu Y, Stevens RG, Hoffman AE, et al. Testing the circadian gene hypothesis in prostate cancer: a population-based case-control study [J]. Cancer Res, 2009, 69(24): 9315-9322.
